Literature DB >> 28288846

Pleiotropic FTY720 Is a Specific and Potent Therapy for Hypertrophic Scars.

Fen Shi1, Xiaoling Cao2, Zhicheng Hu1, Da Ma3, Dong Guo4, Jian Zhang5, Changlin Zhang6, Peng Liu1, Shanqiang Qu1, Jiayuan Zhu1, Wuguo Deng7, Bing Tang8.   

Abstract

Hypertrophic scarring (HS) is a fibrotic skin condition characterized by aberrant fibroblast phenotypes and excessive deposition of extracellular matrix components. 2-Amino-2-[2-(4-octylphenyl)]-1, 3-propanediol hydrochloride (FTY720), an immunomodulator approved for treating multiple sclerosis, is reported to attenuate fibrosis in multiple disease models. Here we found that FTY720 could significantly attenuate the proliferation and fibrosis in HS fibroblasts (HSFs) and in an animal HS model. Upon treating HSFs or normal dermal fibroblasts with FTY720 at different concentrations for different time periods, we found that FTY720 presented a pleiotropic effect specifically on HSFs but not NFs, including reducing cell viability, arresting cell cycle progression at the G0/G1 phase, promoting apoptosis, inhibiting migration and contraction, and suppressing the expressions of α-smooth muscle actin, collagen I, and collagen III. Mechanistic studies showed that the antifibrotic activities of FTY720 were potentially mediated through sphingosine 1-phosphate receptor 5 to inhibit the protein kinase B/mTOR/p70S6K, but not the Smad, signaling pathway. The in vitro actions of FTY720 also translated into a rabbit ear HS model, stimulating the healing of HS. These findings collectively suggest that FTY720 targets multiple phenotypes of HSFs and is a promising therapeutic agent for HS.
Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28288846     DOI: 10.1016/j.jid.2017.02.978

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  7 in total

1.  The ASIC3-M-CSF-M2 macrophage-positive feedback loop modulates fibroblast-to-myofibroblast differentiation in skin fibrosis pathogenesis.

Authors:  Jun-Jie Wu; Zi-Li Sun; Si-Yu Liu; Zhong-Hua Chen; Zheng-Dong Yuan; Ming-Li Zou; Ying-Ying Teng; Yue-Yue Li; Dan-Yang Guo; Feng-Lai Yuan
Journal:  Cell Death Dis       Date:  2022-06-06       Impact factor: 9.685

2.  Lycorine Inhibits Hypertrophic Scar Formation by Inducing ROS-Mediated Apoptosis.

Authors:  Yunxian Dong; Dongming Lv; Zirui Zhao; Zhongye Xu; Zhicheng Hu; Bing Tang
Journal:  Front Bioeng Biotechnol       Date:  2022-05-24

3.  Sphingosine-1-Phosphate Receptor 5 Modulates Early-Stage Processes during Fibrogenesis in a Mouse Model of Systemic Sclerosis: A Pilot Study.

Authors:  Katrin G Schmidt; Martina Herrero San Juan; Sandra Trautmann; Lucija Berninger; Anja Schwiebs; Florian M Ottenlinger; Dominique Thomas; Frank Zaucke; Josef M Pfeilschifter; Heinfried H Radeke
Journal:  Front Immunol       Date:  2017-09-29       Impact factor: 7.561

4.  FTY720 ameliorates GvHD by blocking T lymphocyte migration to target organs and by skin fibrosis inhibition.

Authors:  Jaeyoon Ryu; Jooyeon Jhun; Min-Jung Park; Jin-Ah Baek; Se-Young Kim; Keun-Hyung Cho; Jeong-Won Choi; Sung-Hwan Park; Jong Young Choi; Mi-La Cho
Journal:  J Transl Med       Date:  2020-06-06       Impact factor: 5.531

5.  The Akt/FoxO/p27Kip1 axis contributes to the anti-proliferation of pentoxifylline in hypertrophic scars.

Authors:  Fangfang Yang; Erfei Chen; Yunshu Yang; Fu Han; Shichao Han; Gaofeng Wu; Min Zhang; Jian Zhang; Juntao Han; Linlin Su; Dahai Hu
Journal:  J Cell Mol Med       Date:  2019-07-03       Impact factor: 5.310

Review 6.  Sphingosine 1-Phosphate (S1P)/ S1P Receptor Signaling and Mechanotransduction: Implications for Intrinsic Tissue Repair/Regeneration.

Authors:  Chiara Sassoli; Federica Pierucci; Sandra Zecchi-Orlandini; Elisabetta Meacci
Journal:  Int J Mol Sci       Date:  2019-11-07       Impact factor: 5.923

Review 7.  Sphingosine 1-Phosphate Signaling at the Skin Barrier Interface.

Authors:  Kana Masuda-Kuroki; Anna Di Nardo
Journal:  Biology (Basel)       Date:  2022-05-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.